机器人辅助根治性前列腺切除术中逆行释放神经血管束并保留背静脉复合体的功能结局
该前瞻性非对照病例系列纳入128例连续接受机器人辅助根治性前列腺切除术(RARP)的患者,采用逆行释放神经血管束并保留背静脉复合体的技术改良。结果显示总体切缘阳性率为13.3%,pT2和pT3分别为9%和27%;术后1年尿控率达98.4%,86%的患者保持勃起功能。结论认为该技术安全且肿瘤学与功能结局良好。
要点
- 逆行释放神经血管束并保留背静脉复合体的RARP技术安全可行。
- 总体切缘阳性率13.3%,pT2为9%,pT3为27%。
- 术后1年尿控率98.4%,86%患者保持勃起功能。
核心结论
- 逆行释放神经血管束并保留背静脉复合体的RARP技术安全,且与良好的肿瘤学及功能结局相关。
研究设计与样本
- 前瞻性非对照病例系列,纳入128例连续接受RARP的患者,由单一术者完成。
主要发现
- 中位年龄63.5岁,中位皮肤至皮肤时间78分钟,中位住院1天,7例(5.5%)住院超过24小时。
- 中位术中出血200ml,2例(1.6%)术后需输血,4例(3.1%)发生Clavien-Dindo≥3级并发症。
- 9例(7%)出现生化复发(BCR),中位至BCR时间6个月。
- 总体切缘阳性率13.3%(17/128),pT2为9%(8/89),pT3为27%(9/38)。
- 术后即刻尿控率85.9%,1年尿控率98.4%;术后1个月53%(60例)保持勃起功能,1年时86%(98/113)保持勃起功能。
关键数值与推荐
- 勃起功能定义为SHIM评分≥17;尿控定义为不使用尿垫。
- 生化复发定义为PSA>0.2ng/ml;并发症按Clavien-Dindo分级。
临床怎么用
- 该技术可在RARP中用于保留前列腺前侧的神经与血管结构,以优化术后尿控和勃起功能恢复。
局限性
- 本研究为非对照研究,缺乏比较组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Robot-assisted laparoscopic radical prostatectomy (RARP) presents consistent oncological outcomes for prostate cancer; yet continence and potency results are not uniform. We present a technical modification for RARP which preserves the nerves and vascular structures anterior to the prostate aiming to optimize functional outcomes. OBJECTIVE: To present oncological and functional results of a modified technique for RARP. DESIGN, SETTING, AND PARTICIPANTS: Prospective, noncontrolled case series including 128 consecutive patients undergoing RARP performed by a single surgeon (R.F.C). SURGICAL PROCEDURE: RARP with retrograde release of the neurovascular bundle and preservation of dorsal venous complex. MEASUREMENTS: Potency was defined as a Sexual Health Inventory for Men score of ≥17; continence was defined as use of no pads. Oncological results analyzed were positive surgical margins (PSM) rates and biochemical recurrence (BCR)-free survival. BCR was defined as prostate-specific antigen >0.2ng/ml. Complications were graded according to the Clavien-Dindo classification. RESULTS AND LIMITATIONS: Median patient age was 63.5 yr. Median skin-to-skin time was 78min. Median length of hospital stay was 1 d, with seven patients (5.5%) hospitalized for more than 24h. Median intraoperative bleeding was 200ml and two patients required postoperative blood transfusion (1.6%). Four patients (3.1%) had grade ≥3 complications. Biochemical recurrence (BCR) occurred in nine of 128 patients (7%) and median time to BCR was 6 mo. Overall PSM rate was 13.3% (17 of 128 patients). PSM rate was 9% among patients with pT2 disease (8/89) and 27% in patients with pT3 (9/38). Continence was reached immediately in 85.9% of the patients and 98.4% were continent at1 yr. At 1 mo postoperatively, 60 patients were potent (53%), while 98 patients among 113 (86%) were potent 1 yr after surgery. A limitation of this study is that it was a noncomparative study. CONCLUSIONS: Retrograde release of the neurovascular bundle with preservation of dorsal venous complex during RARP is safe and associated with excellent oncological and functional outcomes. Future comparative studies are needed. PATIENT SUMMARY: Robot-assisted radical prostatectomy (RARP) presents consistent oncological outcomes for prostate cancer; yet continence and potency results are not uniform. We present a technical modification for RARP aiming to preserve the nerves and vascular structures anterior to the prostate. We evaluated 128 consecutive patients with clinically localized or locally advanced prostate cancer undergoing RARP with our modified technique of retrograde release of the neurovascular bundles with dorsal vein sparing. We have shown that this technique is safe, effective and associated with early recovery of continence and sexual function after surgery.
引用
- de Carvalho PA, Barbosa JABA, Guglielmetti GB, et al. Retrograde Release of the Neurovascular Bundle with Preservation of Dorsal Venous Complex During Robot-assisted Radical Prostatectomy: Optimizing Functional Outcomes. Eur Urol. 2018. PMID: 30041833. doi:10.1016/j.eururo.2018.07.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。